IRIS
PERNO, CARLO-FEDERICO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 135.351
EU - Europa 10.586
AS - Asia 4.710
OC - Oceania 120
SA - Sud America 91
AF - Africa 59
Continente sconosciuto - Info sul continente non disponibili 41
Totale 150.958
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 135.260
SG - Singapore 2.184
UA - Ucraina 1.845
DE - Germania 1.837
SE - Svezia 1.304
CN - Cina 1.232
IE - Irlanda 1.227
IT - Italia 1.115
FR - Francia 712
KR - Corea 689
PL - Polonia 639
RU - Federazione Russa 626
GB - Regno Unito 557
FI - Finlandia 417
IQ - Iraq 161
AU - Australia 117
BE - Belgio 100
VN - Vietnam 99
CA - Canada 77
JP - Giappone 66
CZ - Repubblica Ceca 61
IR - Iran 54
IN - India 50
NL - Olanda 43
BR - Brasile 38
HK - Hong Kong 35
TR - Turchia 35
EU - Europa 34
ES - Italia 30
CL - Cile 23
CH - Svizzera 21
CM - Camerun 15
PK - Pakistan 14
RO - Romania 14
GR - Grecia 10
IL - Israele 10
UZ - Uzbekistan 10
ZA - Sudafrica 10
ID - Indonesia 9
KG - Kirghizistan 9
PE - Perù 8
AE - Emirati Arabi Uniti 7
AR - Argentina 7
BD - Bangladesh 7
CO - Colombia 7
DM - Dominica 7
EC - Ecuador 7
A2 - ???statistics.table.value.countryCode.A2??? 6
DK - Danimarca 6
PH - Filippine 6
AT - Austria 5
BG - Bulgaria 5
GH - Ghana 5
NG - Nigeria 5
SA - Arabia Saudita 5
UG - Uganda 5
ET - Etiopia 4
KZ - Kazakistan 4
MX - Messico 4
MY - Malesia 4
TW - Taiwan 4
AM - Armenia 3
EG - Egitto 3
MN - Mongolia 3
NZ - Nuova Zelanda 3
CI - Costa d'Avorio 2
CR - Costa Rica 2
HU - Ungheria 2
LK - Sri Lanka 2
LY - Libia 2
NP - Nepal 2
PT - Portogallo 2
SD - Sudan 2
TH - Thailandia 2
A1 - Anonimo 1
AL - Albania 1
AZ - Azerbaigian 1
BO - Bolivia 1
DO - Repubblica Dominicana 1
EE - Estonia 1
HR - Croazia 1
KE - Kenya 1
KH - Cambogia 1
LB - Libano 1
LV - Lettonia 1
MD - Moldavia 1
NO - Norvegia 1
QA - Qatar 1
SC - Seychelles 1
SK - Slovacchia (Repubblica Slovacca) 1
SO - Somalia 1
TG - Togo 1
TN - Tunisia 1
TZ - Tanzania 1
VA - Santa Sede (Città del Vaticano) 1
Totale 150.958
Salva come PNG Salva come JPEG
Città #
Woodbridge 41.979
Wilmington 37.022
Houston 32.266
Fairfield 3.983
Ann Arbor 3.396
Chandler 1.999
Singapore 1.890
Ashburn 1.784
Jacksonville 1.685
Seattle 1.659
Cambridge 1.364
Dublin 1.157
Medford 916
Dearborn 671
Kraków 626
Beijing 583
Santa Clara 496
Rome 433
Lawrence 432
Moscow 393
New York 294
Mülheim 273
San Diego 211
Menlo Park 210
Milan 174
Zhengzhou 155
Falls Church 106
Boardman 100
Brussels 95
University Park 87
Redwood City 79
Dong Ket 78
Palo Alto 77
London 76
Norwalk 75
Phoenix 69
Mountain View 65
San Mateo 62
Creede 59
Nanjing 59
Verona 57
San Francisco 52
Shanghai 47
Saint Petersburg 44
Guangzhou 42
Hefei 42
Munich 42
Kunming 41
Baghdad 38
Toronto 35
Colorado Springs 34
Sydney 33
Melbourne 32
Brno 30
Olomouc 30
Helsinki 28
Jinan 28
Canberra 27
Nanchang 27
Los Angeles 25
Nuremberg 25
Hong Kong 24
Cedarhurst 22
Indiana 22
Nürnberg 22
Sulaymaniyah 22
São Paulo 20
Hanoi 19
Hangzhou 18
Daejeon 17
Lake Forest 17
Prescot 16
Arbil 15
Detroit 15
Hebei 15
Tokyo 15
Kilburn 14
San Jose 14
Seoul 14
Amsterdam 13
Fuzhou 13
Tehran 13
Wuhan 13
Erbil 12
Ottawa 12
Chicago 11
Hounslow 11
Madrid 11
Redmond 11
Auburn Hills 10
Bari 10
Sacramento 10
Lappeenranta 9
Pune 9
Shenyang 9
Chiswick 8
Council Bluffs 8
Karbala 8
Montréal 8
West Jordan 8
Totale 138.435
Salva come PNG Salva come JPEG
Nome #
1,2,3-TRIAZOLE-[2',5'-BIS-O-(TERT-BUTYLDIMETHYLSILYL)-BETA-D-RIBOFURANOSYL]-3'-SPIRO-5''-(4''-AMINO-1'',2''-OXATHIOL 2'',2''-DIOXIDE) (TSAO) ANALOGS - SYNTHESIS AND ANTI-HIV-1 ACTIVITY 718
Antibiotic susceptibility of vancomyin and nitrofurantoin in Staphylococcus aureus isolated from burnt patients in Sulaimaniyah, Iraqi Kurdistan 674
HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels 509
The Genotypic False Positive Rate Determined by Population V3-Sequencing can Predict the Burden of X4 Quasispecies Detected by Pyrosequencing 494
Persistent risk of HBV reactivation despite extensive lamivudine prophylaxis in haematopoietic stem cell transplant recipients who are anti-HBc-positive or HBV-negative recipients with an anti-HBc-positive donor 493
Therapeutic strategies towards HIV-1 infection in macrophages 471
Occupational HIV infection in a research laboratory with unknown mode of transmission: a case report 470
Progesterone and Melanoma Cells: An Old Story Suspended between Life and Death 463
Virologic correlates of adherence to antiretroviral medications and therapeutic failure 459
Treatment with the fusion inhibitor enfuvirtide influences the appearance of mutations in the human immunodeficiency virus type 1 regulatory protein rev 458
A killer mimotope with therapeutic activity against AIDS-related opportunistic micro-organisms inhibits ex-vivo HIV-1 replication 448
Two different patterns of mutations are involved in the genotypic resistance score for atazanavir boosted versus unboosted by ritonavir in multiple failing patients 447
Thymosin α 1 potentiates the release by CD8(+) cells of soluble factors able to inhibit HIV-1 and human T lymphotropic virus 1 infection in vitro 447
Snapshot on drug-resistance rate and profiles in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice 445
Potential for new antiretrovirals to address unmet needs in the management of HIV-1 infection 444
Carbohydrate-binding agents (CBAs) inhibit HIV-1 infection in human primary monocyte-derived macrophages (MDMs) and efficiently prevent MDM-directed viral capture and subsequent transmission to CD4(+) T lymphocytes 444
Characterization and structural analysis of novel mutations in human immunodeficiency virus type 1 reverse transcriptase involved in the regulation of resistance to nonnucleoside inhibitors 444
HCV-RNA quantification in liver bioptic samples and extrahepatic compartments, using the abbott RealTime HCV assay 443
Novel drug resistance mutations in HIV: Recognition and clinical relevance 442
Characterization of drug-resistance mutations in HIV-1 isolates from non-HAART and HAART treated patients in Burkina Faso 441
Hepatitis B surface antigen genetic elements critical for immune escape correlate with hepatitis B virus reactivation upon immunosuppression 441
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study 441
Comparative antiviral activity of integrase inhibitors in human monocyte-derived macrophages and lymphocytes 439
Viral causes of influenza-like illness: Insight from a study during the winters 2004-2007 439
Mannose-specific plant lectins from the Amaryllidaceae family qualify as efficient microbicides for prevention of human immunodeficiency virus infection 435
Human immunodeficiency virus infection and acquired immunodeficiency syndrome dementia complex: Role of cells of monocyte-macrophage lineage 435
Understanding HIV compartments and reservoirs 435
Red blood cells mediated delivery of 9-(2-phosphonylmethoxyethyl)adenine to primary macrophages: Efficiency, metabolism and activity against human immunodeficiency virus or herpes simplex virus 434
Macrophages and HIV infection: Therapeutical approaches toward this strategic virus reservoir 433
Drug-resistance development differs between HIV-1-infected patients failing first-line antiretroviral therapy containing nonnucleoside reverse transcriptase inhibitors with and without thymidine analogues 433
Early antiretroviral treatment (eART) limits viral diversity over time in a long-term HIV viral suppressed perinatally infected child 433
Specific mutations in the C-terminus domain of HBV surface antigen significantly correlate with low level of serum HBV-DNA in patients with chronic HBV infection 432
Lamivudine-resistance mutations can be selected even at very low levels of hepatitis B viraemia 431
A multicenter evaluation of the Abbott RealTime HCV Genotype II assay 431
Nucleotide polymorphisms in the 5'-UTR region of HCV can affect the ability of two widely used assays to assign an HCV genotype 431
Successful switch to tenofovir after suboptimal response to entecavir in an immunocompromised patient with chronic hepatitis B and without genotypic hepatitis B virus resistance. 430
A multi-targeted drug candidate with dual anti-HIV and anti-HSV activity 429
Viro-immunological response of drug-naive HIV-1-infected patients starting a first-line regimen with viraemia >500,000 copies/ml in clinical practice 429
Thymosin alpha 1 and HIV-1: Recent advances and future perspectives 429
Structural modifications induced by specific HIV-1 protease-compensatory mutations have an impact on the virological response to a first-line lopinavir/ritonavir-containing regimen 427
Influenza virus A (H5N1): A pandemic risk? 426
Novel HBsAg mutations correlate with hepatocellular carcinoma, hamper HBsAg secretion and promote cell proliferation in vitro 426
Impact of HIV-1 reverse transcriptase polymorphism F214L on virological response to thymidine analogue-based regimens in antiretroviral therapy (ART)-naive and ART-experienced patients 425
HIV fitness and resistance as covariates associated with the appearance of mutations under antiretroviral treatment 425
Impact of different HIV resistance interpretation by distinct systems on clinical utility of resistance testing. 425
Minor mutations in HIV protease at baseline and appearance of primary mutation 90M in patients for whom their first protease-inhibitor antiretroviral regimens failed 425
Population dynamics of HIV-1 subtype B in a cohort of men-having-sex-with-men in Rome, Italy 424
KI and WU polyomaviruses and CD4+ cell counts in HIV-1- infected patients , Italy 424
Risk of failure in patients with 215 HIV-1 revertants starting their first thymidine analog-containing highly active antiretroviral therapy 424
Comparative Analysis of Drug Resistance Among B and the Most Prevalent Non-B HIV Type 1 Subtypes (C, F, and CRF02_AG) in Italy 423
Immunomodulatory activity of 9-(2-phosphonyl-methoxyethyl)adenine (PMEA), a potent anti-HIV nucleotide analogue, on in vivo murine models 422
Involvement of novel human immunodeficiency virus type 1 reverse transcriptase mutations in the regulation of resistance to nucleoside inhibitors 422
HIV-1-associated dementia during HAART therapy 422
Advances in macrophage and dendritic cell biology in HIV-1 infection stress key understudied areas in infection, pathogenesis, and analysis of viral reservoirs 421
Monitoring of KI and WU polyomaviruses in hematopoietic stem cell transplant patients 420
Hepatitis C virus RNA levels at week-2 of telaprevir/boceprevir administration are predictive of virological outcome 420
Activity of the (R)-Enantiomers of 9-(2-phosphonylmethoxypropyl)-adenine and 9-(2-phosphonylmethoxypropyl)-2,6-diaminopurine against human immunodeficiency virus in different human cell systems 419
Identification of the novel KI polyomavirus in the respiratory tract of an Italian patient 418
Potent inhibition of human immunodeficiency virus and herpes simplex virus type 1 by 9-(2-phosphonylmethoxyethyl)adenine in primary macrophages is determined by drug metabolism, nucleotide pools, and cytokines 418
Specific enfuvirtide-associated mutational pathways in HIV-1 Gp41 are significantly correlated with an increase in CD4(+) cell count, despite virological failure 418
Characterization of drug-resistance mutations in HBV D-genotype chronically infected patients, naïve to antiviral drugs. 418
Effect of maraviroc on non-R5 tropic HIV-1: Refined analysis of subjects from the phase IIb study A4001029 417
Kinetics of hepatitis C virus RNA decay, quasispecies evolution and risk of virological failure during telaprevir-based triple therapy in clinical practice 417
Inhibition of human immunodeficiency virus (HIV-1) infection in human peripheral blood leucocytes-SCID reconstituted mice by rapamycin 416
Viro-immunologic response to ritonavir-boosted or unboosted atazanavir in a large cohort of multiply treated patients: the CARe Study 416
HIV and cells of macrophage/dendritic lineage and other non-T cell reservoirs: new answers yield new questions 415
Epidemiological network analysis in HIV-1 B infected patients diagnosed in Italy between 2000 and 2008 414
Characterization of novel HIV drug resistance mutations using clustering, multidimensional scaling and SVM-based feature ranking 413
Nerve growth factor is an autocrine factor essential for the survival of macrophages infected with HIV 413
Rapid prediction of sustained virological response in patients chronically infected with HCV by evaluation of RNA decay 48h after the start of treatment with pegylated interferon and ribavirin 413
Characterization of the patterns of drug-resistance mutations in newly diagnosed HIV-1 infected patients naive to the antiretroviral drugs 413
Excretion of the novel polyomaviruses KI and WU in the stool of patients with hematological disorders 412
'Sentinel' mutations in standard population sequencing can predict the presence of HIV-1 reverse transcriptase major mutations detectable only by ultra-deep pyrosequencing 412
Primary macrophages infected by human immunodeficiency virus trigger CD95-mediated apoptosis of uninfected astrocytes 411
Drug-loaded red blood cell-mediated clearance of HIV-1 macrophage reservoir by selective inhibition of STAT1 expression 411
Correlation between induction of lymphocyte apoptosis and prostaglandin E2 production by macrophages infected with HIV 411
Novel HBsAg markers tightly correlate with occult HBV infection and strongly affect HBsAg detection. 411
Molecular analysis based on mtLSU-rRNA and DHPS sequences of Pneumocystis jirovecii from immunocompromised and immunocompetent patients in Italy 410
Is dual therapy with raltegravir and protease inhibitors a feasible option in rescue strategy in HIV-1 infection? 408
Specific HbsAg genetic determinants are associated with occult HBV infection in vivo and HbsAg detection 407
When and how to use maraviroc in HIV-infected patients 407
Improving adherence to highly active anti-retroviral therapy in Africa: the DREAM programme in Mozambique 406
Analysis of single-nucleotide polymorphisms (SNPs) in human CYP3A4 and CYP3A5 genes: potential implications for the metabolism of HIV drugs 406
Late-onset haemorrhagic cystitis in children after haematopoietic stem cell transplantation for thalassaemia and sickle cell anaemia: a prospective evaluation of polyoma (BK) virus infection and treatment with cidofovir (CDV) 405
Rate of CD4+ cell count increase over periods of viral load suppression: relationship with the number of previous virological failures 404
Different evolution of genotypic resistance profiles to emtricitabine versus lamivudine in tenofovir-containing regimens 404
Q151M-mediated multinucleoside resistance: prevalence, risk factors, and response to salvage therapy 403
Improved antiviral activity of the aryloxymethoxyalaninyl phosphoramidate (APA) prodrug of abacavir (ABC) is due to the formation of markedly increased carbovir 5 '-triphosphate metabolite levels 402
Overcoming resistance to existing therapies in HIV-infected patients: The role of new antiretroviral drugs 402
Effective program against mother-to-child transmission of HIV at Saint Camille Medical Centre in Burkina Faso 402
Macrophage depletion induced by clodronate-loaded erythrocytes 402
Comparative evaluation of subtyping tools for the surveillance of newly emerging HIV-1 strains 402
Specific mutations in HIV-1 gp41 are associated with immunological success in HIV-1-infected patients receiving enfuvirtide treatment 401
Pathogen safety of long-term treatments for bleeding disorders: (un)predictable risks and evolving threats 401
Highly active antiretroviral therapy reduces the age-associated risk of dementia in a cohort of older HIV-1-infected patients 400
HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors 399
Specific HBSAG Genetic- Determinants are associated with occult HBV-infection in vivo and HBSAG detection 399
Intratype variations of HPV 31 and 58 in Italian women with abnormal cervical cytology. 398
Molecular and structural aspects of clinically relevant mutations related to the approved non-nucleoside inhibitors of HIV-1 reverse transcriptase 398
The potential role of pre-transplant HBcIgG seroposivity as predictor of clinically relevant cytomegalovirus infection in patients with lymphoma undergoing autologous hematopoietic stem cell transplantation: A study from the Rome Transplant Network 398
Totale 43.065
Salva come PNG Salva come JPEG
Categoria #
all - tutte 275.073
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 275.073
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202033.440 0 0 2.867 3.791 3.500 4.338 3.596 3.566 3.423 3.243 2.399 2.717
2020/202122.641 2.623 2.647 2.486 2.985 2.177 2.430 2.966 2.133 500 485 830 379
2021/20225.056 234 358 337 256 212 530 210 180 770 485 233 1.251
2022/20236.057 669 419 208 720 479 1.343 432 463 490 110 501 223
2023/20242.042 272 197 144 72 260 340 90 82 55 89 36 405
2024/20253.592 424 2.634 534 0 0 0 0 0 0 0 0 0
Totale 152.080